Eisai Reports Lecanemab Revenue Soars Over 2000% to $194 Million in First Three Quarters of FY2024

On February 7, Eisai released its Q3 earnings report for the fiscal year 2024. First three quarters（2024.4.1--2024.12.31），Eisai's total revenue was 601.2 billion yen, approximately $3.938 billion.(Exchange rate calculated at 1 yen = 0.00655 USD, same as below)，An increase of approximately 9% year-over-year。

Among them,Pharmaceutical Business Revenue: 569.1 Billion Yen(Approximately USD 3.728 billion), an increase of approximately 8% year-over-yearR&D investment reached 125.3 billion yen (approximately 821 million U.S. dollars), a year-on-year increase of 0.6%.

InterceptSource: Eisai Financial Report (same as below)

The main drivers of performance growth come from three products, namely: anti-tumor drugs Lenvima(Lenvatinib)、 New Type of Insomnia DrugDayvigo (Lemborexant), Alzheimer's Disease Drugs LEQEMBI(Leqembi)。The total revenue of these three products reached 318.1 billion yen.，Approximately USD 2.084 billion, an increase of approximately 24% year-over-year.

Lenvatinib is an orally administered multi-kinase inhibitor that dually suppresses VEGFR and FGFR, serving as a cornerstone product in Eisai's oncology portfolio. The drug has been approved for six indications across five cancer types, primarily endometrial cancer and renal cell carcinoma.

The first three quarters of 2024,Lenvatinib Revenue 248.1 Billion Yen(approximately 1.625 billion US dollars),An increase of 11.1% year-on-yearThe main driver of growth was still the U.S. market, with revenue reaching 175.5 billion yen, an increase of approximately 15% year-on-year.

New Type of Insomnia MedicationDayvigo Revenue 40.5 Billion Yen(approximately 265 million US dollars),An increase of nearly 30% year-on-year。

Leqembi Revenue Maintains Steady Growth. In the First Three Quarters,Lecanemab's Global Revenue Reaches 29.6 Billion Yen(approximately 194 million US dollars), an increase of 2014% year-on-yearIn China, lecanemab was launched at the end of June 2024.Generated 2.8 Billion Yen(approximately 0.18 billion US dollars)IncomeEisai expects the drug to achieve the projected revenue target of 42.5 billion yen in the fiscal year 2024.

Leqembi has already been approved for marketing in 10 countries and regions, and is currently under regulatory review in 17 countries and regions. In addition, Eisai has launched a subcutaneous injection formulation of Leqembi and submitted its application for market approval to the U.S. FDA, with a PDUFA date set for August 31, 2025.

Scan the WeChat QR code, add the editor of the Biologics Circle, and those who meet the requirements can join.

Biological Products WeChat Group!